Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

However, GLP-1-based therapies aren't going to be the only option in the weight loss medicines market forever. Some companies are pursuing other approaches that could be even more effective or ...

With so many treatments and drugs accessible ... but the result is a curated list that you can rely on for effective weight ...

It's been a very difficult year for Walgreens Boots Alliance (NASDAQ: WBA), which has seen its stock lose two-thirds of its ...

When you think of brain stimulating medtech, startups building wearables as therapeutics probably aren't the first thing that ...

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company ...

Beta is a measurement of market risk or volatility that indicates how much the price of a stock tends to fluctuate up and ...

A program to accelerate drug trials often provides the market with new drugs that are only marginally more effective, but ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Between Viking Therapeutics and Summit Therapeutics, investing $1,500 in Viking makes more sense right now, though it is a ...

In a report released on October 10, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research ...